Inventiva (IVA) said late Wednesday that last patient completed the final 72-week visit in its NATiV3 phase 3 trial evaluating lanifibranor for patients with metabolic dysfunction-associated steatohepatitis, a common and progressive chronic liver disease, with moderate to advanced fibrosis.

All patients have completed the 72-week treatment period, according to a statement.

The study enrolled 1,009 patients in the main cohort and 410 patients in the exploratory cohort, the company said.

Inventiva said it expects to report topline results in Q4, and plans to seek regulatory approval in H1 of 2027, if results are favorable.

Also, the company updated timing of its H1 financial results to Sept. 28, revised from the prior date of Sept. 25.